Camurus AB (CAMX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Camurus AB (CAMX) has a cash flow conversion efficiency ratio of 0.060x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr255.43 Million ≈ $27.49 Million USD) by net assets (Skr4.24 Billion ≈ $455.80 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Camurus AB - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Camurus AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Camurus AB total liabilities for a breakdown of total debt and financial obligations.
Camurus AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Camurus AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Marzetti Company
NASDAQ:MZTI
|
0.086x |
|
Organización Soriana S. A. B. de C. V
MX:SORIANAB
|
0.047x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
Unilever Indonesia Tbk
JK:UNVR
|
0.579x |
|
Zealand Pharma A/S
CO:ZEAL
|
-0.070x |
|
LIFE360 Inc
AU:360
|
0.069x |
|
Shanghai Jin Jiang International Hotels Development Co Ltd A
SHG:600754
|
0.092x |
|
Jubilant Foodworks Limited
NSE:JUBLFOOD
|
0.403x |
Annual Cash Flow Conversion Efficiency for Camurus AB (2012–2025)
The table below shows the annual cash flow conversion efficiency of Camurus AB from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see CAMX stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.24 Billion ≈ $455.80 Million |
Skr869.30 Million ≈ $93.55 Million |
0.205x | +74.02% |
| 2024-12-31 | Skr3.29 Billion ≈ $354.02 Million |
Skr387.99 Million ≈ $41.75 Million |
0.118x | -70.98% |
| 2023-12-31 | Skr1.49 Billion ≈ $160.67 Million |
Skr606.88 Million ≈ $65.31 Million |
0.406x | +299.53% |
| 2022-12-31 | Skr994.67 Million ≈ $107.04 Million |
Skr101.20 Million ≈ $10.89 Million |
0.102x | +160.22% |
| 2021-12-31 | Skr848.91 Million ≈ $91.36 Million |
Skr-143.43 Million ≈ $-15.44 Million |
-0.169x | +40.05% |
| 2020-12-31 | Skr847.44 Million ≈ $91.20 Million |
Skr-238.83 Million ≈ $-25.70 Million |
-0.282x | +55.98% |
| 2019-12-31 | Skr631.63 Million ≈ $67.97 Million |
Skr-404.36 Million ≈ $-43.52 Million |
-0.640x | +41.06% |
| 2018-12-31 | Skr252.32 Million ≈ $27.15 Million |
Skr-274.08 Million ≈ $-29.50 Million |
-1.086x | -105.94% |
| 2017-12-31 | Skr385.00 Million ≈ $41.43 Million |
Skr-203.07 Million ≈ $-21.85 Million |
-0.527x | -43.27% |
| 2016-12-31 | Skr564.42 Million ≈ $60.74 Million |
Skr-207.79 Million ≈ $-22.36 Million |
-0.368x | -4068.62% |
| 2015-12-31 | Skr640.56 Million ≈ $68.93 Million |
Skr-5.66 Million ≈ $-608.78K |
-0.009x | -101.57% |
| 2014-12-31 | Skr123.46 Million ≈ $13.29 Million |
Skr69.43 Million ≈ $7.47 Million |
0.562x | -82.74% |
| 2013-12-31 | Skr50.05 Million ≈ $5.39 Million |
Skr163.06 Million ≈ $17.55 Million |
3.258x | +429.67% |
| 2012-12-31 | Skr40.21 Million ≈ $4.33 Million |
Skr24.73 Million ≈ $2.66 Million |
0.615x | -- |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more